<DOC>
	<DOC>NCT01130168</DOC>
	<brief_summary>This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in participants with hypertension.</brief_summary>
	<brief_title>The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Participant is a male or female between 30 and 65 years of age (inclusive) at the prestudy (screening) Female participant of childbearing potential must have a negative pregnancy test Participant has a brachial systolic blood pressure &gt;130 mm Hg and &lt;180 mm Hg Participant has a Body Mass Index (BMI) that is &gt;20 kg/m^2 and &lt;35 kg/m^2 Participant has been a nonsmoker and/or has not used nicotine or nicotinecontaining products for at least approximately 6 months Female Participant is pregnant or lactating Participant anticipates the use of NonSteroidal AntiInflammatory Drugs (NSAIDs) other than acetaminophen Participant is currently a user (including "recreational use") of any illicit drugs, has a history of drug or alcohol abuse within approximately 2 years, or has a positive prestudy urine drug screen Participant has a condition for which there is a warning, contraindication, or precaution against the use of ISMN ER including: acute myocardial infarction or congestive heart failure, hypotension, volume depletion, and pregnancy Participant has a history of significant drug allergy or any clinically significant adverse experience of a serious nature related to the administration of either a marketed or an investigational drug, including nitrates, nitrites, Amlodipine, and ISMN ER</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>